Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression.

Mann JR, Backlund MG, Buchanan FG, Daikoku T, Holla VR, Rosenberg DW, Dey SK, DuBois RN.

Cancer Res. 2006 Jul 1;66(13):6649-56.

2.

Prostaglandin catabolic enzymes as tumor suppressors.

Tai HH.

Cancer Metastasis Rev. 2011 Dec;30(3-4):409-17. doi: 10.1007/s10555-011-9314-z. Review.

PMID:
22020925
3.

[Role of prostaglandins in colon cancer].

Myung SJ, Kim IH.

Korean J Gastroenterol. 2008 May;51(5):274-9. Review. Korean.

4.

The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.

Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A.

Carcinogenesis. 2009 Mar;30(3):377-86. doi: 10.1093/carcin/bgp014. Epub 2009 Jan 9. Review.

5.

Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer.

Kochel TJ, Fulton AM.

Prostaglandins Other Lipid Mediat. 2015 Jan-Mar;116-117:99-103. doi: 10.1016/j.prostaglandins.2014.11.003. Epub 2014 Nov 27. Review.

6.

15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer.

Tai HH, Tong M, Ding Y.

Prostaglandins Other Lipid Mediat. 2007 May;83(3):203-8. Epub 2007 Jan 17. Review.

7.

NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions.

Tai HH, Cho H, Tong M, Ding Y.

Curr Pharm Des. 2006;12(8):955-62. Review.

PMID:
16533162
8.

An inflammatory mediator, prostaglandin E2, in colorectal cancer.

Wang D, DuBois RN.

Cancer J. 2013 Nov-Dec;19(6):502-10. doi: 10.1097/PPO.0000000000000003. Review.

Items per page

Supplemental Content

Write to the Help Desk